Biopharmaceutical company Elpis Biopharma and the National Cancer Centre Singapore join forces to drive advancements in cell therapy research within Singapore's medical community.
Elpis Biopharmaceuticals and the National Cancer Centre Singapore (NCCS) have joined forces in a groundbreaking collaboration aimed at making living drugs a reality for patients with cancers that currently lack effective treatment options.
In late July 2025, the two organizations signed a memorandum of understanding (MoU) to conduct translational cell therapy research focused on developing bispecific armored CAR-T cell therapies for solid tumors, including colorectal, pancreatic, and ovarian cancers.
The agreement seeks to leverage Elpis’s leading mRNA display technology combined with NCCS's expertise to accelerate the development and delivery of CAR-T therapies specifically targeting solid tumors. The partnership is currently progressing through early translational research stages, with preclinical and early translational development activities expected.
The focus on bispecific armored CAR-T cells means the therapies will be designed to engage multiple targets or incorporate additional functionalities to enhance efficacy and overcome solid tumor microenvironment challenges. This collaboration is a key step toward enabling broader clinical translation of Elpis's cell therapy technologies.
Professor Lim Soon Thye, CEO of NCCS, stated that the collaboration will enable the evaluation of new technologies for solid tumor cell therapies. Professor Daniel Tan, Head of Division at NCCS, expressed excitement about offering clinical trials and developing novel cell therapies.
The MOU signifies an expansion of Elpis's living drug strategy, and it is a significant collaboration for NCCS's precision immunotherapy program. The partnership will support the development of novel modalities to cell therapy and beyond.
In summary, Elpis Biopharmaceuticals and NCCS are actively collaborating under a newly signed MoU focused on translating bispecific armored CAR-T cell therapies for solid tumors into clinical development, with a particular emphasis on colorectal, pancreatic, and ovarian cancers. The partnership is currently progressing through early translational research stages as of July 2025.
This collaboration between Elpis Biopharmaceuticals and the National Cancer Centre Singapore (NCCS) is centered around the development of bispecific armored CAR-T cell therapies for various medical-conditions like colorectal, pancreatic, and ovarian cancers, which are challenging to treat with current methods. This endeavor is aimed at making progress in the field of science and health-and-wellness, as the partnership seeks to improve treatment options for patients with these types of cancers.
